
    
      Healthy study participants aged 1 year and older will receive two doses of vaccine 14 days
      apart, and will be assessed baseline immunogenicity (pre-vaccination) and 14 days after each
      vaccine dose. Safety data will be collected for 14 days after the first dose and 30 days
      after the second dose.
    
  